Literature DB >> 21856253

Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry.

Rui Li1, Xue Qiao, Qingyan Li, Rong He, Min Ye, Cheng Xiang, Xionghao Lin, Dean Guo.   

Abstract

This paper aims to investigate the metabolism and pharmacokinetics of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor. To improve water solubility, nanoparticle formulations were prepared as curcuminoids-loaded solid lipid nanoparticles (curcuminoids-SLNs) and curcumin-loaded solid lipid nanoparticles (curcumin-SLNs). After intragastric administration to tumor-bearing ICR mice, the plasma and tumor samples were analyzed by liquid chromatography with ion trap mass spectrometry. We discovered that curcuminoids were mainly present as glucuronides in plasma, whereas in free form in tumor tissue. A validated LC/MS/MS method was established to determine the three free curcuminoids in tumor homogenate. Samples were separated on a Zorbax SB-C(18) column, eluted with acetonitrile-water (containing 0.1% formic acid), and detected by TSQ Quantum triple quadrupole mass spectrometer in selected reaction monitoring mode. The method showed good linearity (r(2)=0.997-0.999) over wide dynamic ranges (2-6000 ng/mL). Variations within- and between-batch never exceeded 11.2% and 13.4%, respectively. The extraction recovery rates ranged from 78.3% to 87.7%. The pharmacokinetics of curcuminoids in mice tumor fit two-compartment model and first order elimination. For curcumin-SLNs group, the dosing of 250 mg/kg of curcumin resulted in AUC((0-48 h)) of 2285 ngh/mL and C(max) of 209 ng/mL. For curcuminoids-SLNs group, the dosing equivalent to 138 mg/kg of curcumin resulted in higher tumor concentrations (AUC=2811 ngh/mL, C(max)=285 ng/mL). It appeared that co-existing curcuminoids improved the bioavailability of curcumin.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856253     DOI: 10.1016/j.jchromb.2011.07.042

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  A Novel Triple Stage Ion Trap MS method validated for curcumin pharmacokinetics application: A comparison summary of the latest validated curcumin LC/MS methods.

Authors:  Wenji Li; Hilly Yang; Brian Buckley; Lujing Wang; Ah-Ng Kong
Journal:  J Pharm Biomed Anal       Date:  2018-04-17       Impact factor: 3.935

Review 2.  Heterologous production of curcuminoids.

Authors:  J L Rodrigues; K L J Prather; L D Kluskens; L R Rodrigues
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

Review 3.  Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy.

Authors:  Rama I Mahran; Magda M Hagras; Duxin Sun; Dean E Brenner
Journal:  AAPS J       Date:  2016-10-25       Impact factor: 4.009

4.  Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.

Authors:  Shu Fang Soh; Chiung-Kuei Huang; Soo Ok Lee; Defeng Xu; Shuyuan Yeh; Jun Li; Eu Leong Yong; Yinhan Gong; Chawnshang Chang
Journal:  J Pharm Biomed Anal       Date:  2013-08-27       Impact factor: 3.935

Review 5.  Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects.

Authors:  Raghavendhar R Kotha; Devanand L Luthria
Journal:  Molecules       Date:  2019-08-13       Impact factor: 4.411

Review 6.  Natural product-based nanomedicine: recent advances and issues.

Authors:  Rebekah Watkins; Ling Wu; Chenming Zhang; Richey M Davis; Bin Xu
Journal:  Int J Nanomedicine       Date:  2015-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.